DC ENaC-Dependent Inflammasome Activation Contributes to Salt-Sensitive Hypertension.


Journal

Circulation research
ISSN: 1524-4571
Titre abrégé: Circ Res
Pays: United States
ID NLM: 0047103

Informations de publication

Date de publication:
05 08 2022
Historique:
pubmed: 22 7 2022
medline: 9 8 2022
entrez: 21 7 2022
Statut: ppublish

Résumé

Salt sensitivity of blood pressure is an independent predictor of cardiovascular morbidity and mortality. The exact mechanism by which salt intake increases blood pressure and cardiovascular risk is unknown. We previously found that sodium entry into antigen-presenting cells (APCs) via the amiloride-sensitive epithelial sodium channel EnaC (epithelial sodium channel) leads to the formation of IsoLGs (isolevuglandins) and release of proinflammatory cytokines to activate T cells and modulate salt-sensitive hypertension. In the current study, we hypothesized that ENaC-dependent entry of sodium into APCs activates the NLRP3 (NOD [nucleotide-binding and oligomerization domain]-like receptor family pyrin domain containing 3) inflammasome via IsoLG formation leading to salt-sensitive hypertension. We performed RNA sequencing on human monocytes treated with elevated sodium in vitro and Cellular Indexing of Transcriptomes and Epitopes by Sequencing analysis of peripheral blood mononuclear cells from participants rigorously phenotyped for salt sensitivity of blood pressure using an established inpatient protocol. To determine mechanisms, we analyzed inflammasome activation in mouse models of deoxycorticosterone acetate salt-induced hypertension as well as salt-sensitive mice with ENaC inhibition or expression, IsoLG scavenging, and adoptive transfer of wild-type dendritic cells into NLRP3 deficient mice. We found that high levels of salt exposure upregulates the NLRP3 inflammasome, pyroptotic and apoptotic caspases, and IL (interleukin)-1β transcription in human monocytes. Cellular Indexing of Transcriptomes and Epitopes by Sequencing revealed that components of the NLRP3 inflammasome and activation marker IL-1β dynamically vary with changes in salt loading/depletion. Mechanistically, we found that sodium-induced activation of the NLRP3 inflammasome is ENaC and IsoLG dependent. NLRP3 deficient mice develop a blunted hypertensive response to elevated sodium, and this is restored by the adoptive transfer of NLRP3 replete APCs. These findings reveal a mechanistic link between ENaC, inflammation, and salt-sensitive hypertension involving NLRP3 inflammasome activation in APCs. APC activation via the NLRP3 inflammasome can serve as a potential diagnostic biomarker for salt sensitivity of blood pressure.

Sections du résumé

BACKGROUND
Salt sensitivity of blood pressure is an independent predictor of cardiovascular morbidity and mortality. The exact mechanism by which salt intake increases blood pressure and cardiovascular risk is unknown. We previously found that sodium entry into antigen-presenting cells (APCs) via the amiloride-sensitive epithelial sodium channel EnaC (epithelial sodium channel) leads to the formation of IsoLGs (isolevuglandins) and release of proinflammatory cytokines to activate T cells and modulate salt-sensitive hypertension. In the current study, we hypothesized that ENaC-dependent entry of sodium into APCs activates the NLRP3 (NOD [nucleotide-binding and oligomerization domain]-like receptor family pyrin domain containing 3) inflammasome via IsoLG formation leading to salt-sensitive hypertension.
METHODS
We performed RNA sequencing on human monocytes treated with elevated sodium in vitro and Cellular Indexing of Transcriptomes and Epitopes by Sequencing analysis of peripheral blood mononuclear cells from participants rigorously phenotyped for salt sensitivity of blood pressure using an established inpatient protocol. To determine mechanisms, we analyzed inflammasome activation in mouse models of deoxycorticosterone acetate salt-induced hypertension as well as salt-sensitive mice with ENaC inhibition or expression, IsoLG scavenging, and adoptive transfer of wild-type dendritic cells into NLRP3 deficient mice.
RESULTS
We found that high levels of salt exposure upregulates the NLRP3 inflammasome, pyroptotic and apoptotic caspases, and IL (interleukin)-1β transcription in human monocytes. Cellular Indexing of Transcriptomes and Epitopes by Sequencing revealed that components of the NLRP3 inflammasome and activation marker IL-1β dynamically vary with changes in salt loading/depletion. Mechanistically, we found that sodium-induced activation of the NLRP3 inflammasome is ENaC and IsoLG dependent. NLRP3 deficient mice develop a blunted hypertensive response to elevated sodium, and this is restored by the adoptive transfer of NLRP3 replete APCs.
CONCLUSIONS
These findings reveal a mechanistic link between ENaC, inflammation, and salt-sensitive hypertension involving NLRP3 inflammasome activation in APCs. APC activation via the NLRP3 inflammasome can serve as a potential diagnostic biomarker for salt sensitivity of blood pressure.

Identifiants

pubmed: 35862128
doi: 10.1161/CIRCRESAHA.122.320818
pmc: PMC9357159
mid: NIHMS1820289
doi:

Substances chimiques

Epithelial Sodium Channels 0
Epitopes 0
Inflammasomes 0
Interleukin-1beta 0
NLR Family, Pyrin Domain-Containing 3 Protein 0
Sodium Chloride, Dietary 0
Sodium Chloride 451W47IQ8X
Sodium 9NEZ333N27

Types de publication

Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, N.I.H., Extramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

328-344

Subventions

Organisme : BLRD VA
ID : IK2 BX005376
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL147818
Pays : United States
Organisme : NHLBI NIH HHS
ID : R25 HL145817
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL144941
Pays : United States
Organisme : NHLBI NIH HHS
ID : R03 HL155041
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL144446
Pays : United States
Organisme : NHLBI NIH HHS
ID : P01 HL116263
Pays : United States
Organisme : NHLBI NIH HHS
ID : K01 HL130497
Pays : United States
Organisme : NHLBI NIH HHS
ID : K08 HL153789
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL156759
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR002243
Pays : United States

Références

Hypertension. 2010 Feb;55(2):500-7
pubmed: 20038749
Cell Res. 2015 Aug;25(8):893-910
pubmed: 26206316
Hypertension. 1986 Jun;8(6 Pt 2):II127-34
pubmed: 3522418
Circ Res. 2016 Apr 15;118(8):1233-43
pubmed: 26988069
Cardiovasc Res. 2019 Mar 15;115(4):776-787
pubmed: 30357309
Hypertension. 2020 Feb;75(2):449-457
pubmed: 31865794
J Clin Invest. 2014 Oct;124(10):4642-56
pubmed: 25244096
Lancet. 2012 Dec 15;380(9859):2224-60
pubmed: 23245609
Cardiovasc Res. 2013 Mar 15;97(4):696-704
pubmed: 23263331
Adv Exp Med Biol. 2017;956:61-84
pubmed: 27757935
Cell Metab. 2015 Mar 3;21(3):493-501
pubmed: 25738463
Cell. 2019 Jun 13;177(7):1888-1902.e21
pubmed: 31178118
Curr Opin Lipidol. 2014 Feb;25(1):75-9
pubmed: 24345983
Hypertension. 1991 Jul;18(1):67-71
pubmed: 1860713
J Am Soc Hypertens. 2008 Sep-Oct;2(5):355-65
pubmed: 19727429
Hypertension. 2005 Sep;46(3):481-7
pubmed: 16116042
Br J Pharmacol. 2016 Feb;173(4):752-65
pubmed: 26103560
J Vis Exp. 2019 Mar 5;(145):
pubmed: 30907877
Am J Hypertens. 2006 Dec;19(12):1264-9
pubmed: 17161773
Nature. 2006 Mar 9;440(7081):237-41
pubmed: 16407889
Cell. 2010 Mar 19;140(6):821-32
pubmed: 20303873
Lancet. 2005 Jan 15-21;365(9455):217-23
pubmed: 15652604
FASEB J. 2015 Sep;29(9):3899-910
pubmed: 26054366
Antioxid Redox Signal. 2021 Dec 20;35(18):1477-1493
pubmed: 34569287
Cell Rep. 2017 Oct 24;21(4):1009-1020
pubmed: 29069584
BMJ Open. 2014 Apr 14;4(4):e004549
pubmed: 24732242
Hypertension. 2001 Feb;37(2 Pt 2):429-32
pubmed: 11230313
Cell Mol Life Sci. 2016 Dec;73(24):4611-4622
pubmed: 27491297
Nat Biotechnol. 2018 Jun;36(5):411-420
pubmed: 29608179
Circ Res. 2015 Mar 13;116(6):1022-33
pubmed: 25767287
J Clin Invest. 2015 Nov 2;125(11):4223-38
pubmed: 26485286
Nature. 2010 Apr 29;464(7293):1357-61
pubmed: 20428172
J Mol Cell Cardiol. 2011 Jun;50(6):1026-34
pubmed: 21420414
Hypertension. 2011 Feb;57(2):132-40
pubmed: 21149826
Ann Rheum Dis. 2014 Jun;73(6):1202-10
pubmed: 23687262
Cardiovasc Res. 2021 Apr 23;117(5):1358-1371
pubmed: 33038226
Proc Natl Acad Sci U S A. 2018 Feb 13;115(7):E1530-E1539
pubmed: 29378952
Genomics. 2014 May-Jun;103(5-6):323-8
pubmed: 24703969
J Pharmacol Exp Ther. 2001 Oct;299(1):187-97
pubmed: 11561079
Genome Biol. 2013 Apr 25;14(4):R36
pubmed: 23618408
Brief Funct Genomics. 2017 Jul 1;16(4):194-204
pubmed: 27687708
Exp Cell Res. 1997 Mar 15;231(2):354-62
pubmed: 9087177
Nature. 2013 Apr 25;496(7446):518-22
pubmed: 23467095
Biomed Res Int. 2014;2014:248090
pubmed: 24977143
Cardiovasc Res. 2011 Jul 1;91(1):171-9
pubmed: 21354995
Free Radic Biol Med. 2004 May 1;36(9):1163-74
pubmed: 15082070
Nature. 2013 Apr 25;496(7446):513-7
pubmed: 23467085
Hypertension. 2016 Jul;68(1):195-203
pubmed: 27160204
Curr Opin Immunol. 2009 Feb;21(1):10-6
pubmed: 19223160
Hypertension. 2020 Feb;75(2):477-482
pubmed: 31884854

Auteurs

Ashley Pitzer (A)

Division of Clinical Pharmacology (A.P., F.E., C.L.L., M. Saleem, J.K., T.D., L.A.A., D.M.P., A.K.), Vanderbilt University Medical Center, Nashville, TN.

Fernando Elijovich (F)

Division of Clinical Pharmacology (A.P., F.E., C.L.L., M. Saleem, J.K., T.D., L.A.A., D.M.P., A.K.), Vanderbilt University Medical Center, Nashville, TN.

Cheryl L Laffer (CL)

Division of Clinical Pharmacology (A.P., F.E., C.L.L., M. Saleem, J.K., T.D., L.A.A., D.M.P., A.K.), Vanderbilt University Medical Center, Nashville, TN.

Lale A Ertuglu (LA)

Division of Nephrology (L.A.E., M. Sahinoz), Vanderbilt University Medical Center, Nashville, TN.

Melis Sahinoz (M)

Division of Nephrology (L.A.E., M. Sahinoz), Vanderbilt University Medical Center, Nashville, TN.

Mohammad Saleem (M)

Division of Clinical Pharmacology (A.P., F.E., C.L.L., M. Saleem, J.K., T.D., L.A.A., D.M.P., A.K.), Vanderbilt University Medical Center, Nashville, TN.

Jaya Krishnan (J)

Division of Clinical Pharmacology (A.P., F.E., C.L.L., M. Saleem, J.K., T.D., L.A.A., D.M.P., A.K.), Vanderbilt University Medical Center, Nashville, TN.

Thanvi Dola (T)

Division of Clinical Pharmacology (A.P., F.E., C.L.L., M. Saleem, J.K., T.D., L.A.A., D.M.P., A.K.), Vanderbilt University Medical Center, Nashville, TN.

Luul A Aden (LA)

Division of Clinical Pharmacology (A.P., F.E., C.L.L., M. Saleem, J.K., T.D., L.A.A., D.M.P., A.K.), Vanderbilt University Medical Center, Nashville, TN.

Quanhu Sheng (Q)

Department of Medicine, Department of Biostatistics (Q.S.), Vanderbilt University Medical Center, Nashville, TN.

Michael A Raddatz (MA)

Medical Scientist Training Program, Vanderbilt University, Nashville, TN (M.A.R.).
Department of Medicine, University of California, Los Angeles (M.A.R.).

Celestine Wanjalla (C)

Division of Infectious Diseases, Department of Internal Medicine (C.W., S.P.), Vanderbilt University Medical Center, Nashville, TN.

Suman Pakala (S)

Division of Infectious Diseases, Department of Internal Medicine (C.W., S.P.), Vanderbilt University Medical Center, Nashville, TN.

Sean S Davies (SS)

Department of Pharmacology (S.S.D.), Vanderbilt University, Nashville, TN.
Vanderbilt Institute of Chemical Biology (S.S.D.), Vanderbilt University, Nashville, TN.

David M Patrick (DM)

Division of Clinical Pharmacology (A.P., F.E., C.L.L., M. Saleem, J.K., T.D., L.A.A., D.M.P., A.K.), Vanderbilt University Medical Center, Nashville, TN.
Division of Cardiovascular Medicine (D.M.P.), Vanderbilt University Medical Center, Nashville, TN.
Department of Pediatrics (D.M.P.) Vanderbilt University Medical Center, Nashville, TN.

Valentina Kon (V)

Department of Veterans Affairs, Nashville, TN (V.K.).

Thomas Kleyman (T)

Departments of Medicine, Cell Biology, Pharmacology and Chemical Biology, University of Pittsburgh, PA (T.K.).

Annet Kirabo (A)

Division of Clinical Pharmacology (A.P., F.E., C.L.L., M. Saleem, J.K., T.D., L.A.A., D.M.P., A.K.), Vanderbilt University Medical Center, Nashville, TN.
Vanderbilt Institute for Infection' Immunology' and Inflammation, Vanderbilt University Medical Center, Nashville, TN (A.K.).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH